Medtronic: Earnings to grow faster than sales; Vertex sells future Lexiva royalties to GSK; and much more

> Legendary Duke neurosurgeon Dr. Allan Friedman operated on Senator Ted Kennedy's brain tumor, and there's already significant speculation that the lawmaker will undergo experimental therapy in a follow-up treatment. Report

> Medtronic's newly announced five-year growth targets include expectations for earnings to expand faster than sales and for smaller units to grow more quickly than the company's key heart-rhythm-device business. Release

> Twelve percent of patients who rush to the emergency room are there because of adverse effects from medications, according to a study being published today in the Canadian Medical Association Journal. Report

> Watson Pharmaceuticals got the FDA nod for its potassium-chloride extended-release capsules, the generic equivalent of KV Pharmaceutical's Micro-K Extencaps. Report

> Vertex Pharmaceuticals sold its rights to future royalties in the HIV treatment Lexiva and Agenerase under its license agreement with GlaxoSmithKline for $160 million in cash. Report

> Cephalon and its Cima Labs subsidiary have filed suit against Watson Pharmaceuticals for infringement of patents that cover methods of use for its Fentora pain medication; Cephalon says its patents don't expire until 2019. Report

> Mylan has acquired Merck KGaA's Central & Eastern Europe generics businesses, which include operations in Poland, Hungary, Slovakia, Slovenia and the Czech Republic; the deal stems from Mylan's buyout last year of Merck generics operations in several other regions. Report

> GlaxoSmithKline and Ligand Pharmaceuticals won a key endorsement for Promacta for the short-term treatment of people with chronic immune thrombocytopenic purpura, or ITP. Promacta report

> France's Transgene is taking the wraps off of positive Phase IIb data for its experimental cancer vaccine, TG4010. Transgene report

> High school biology students are getting a chance to study drug development in school labs. Report

And Finally... Now here's an innovation: a T-shirt that, like your mother, constantly reminds you sit up straight. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.